Ranking · Unmet Need
Trial Gap Index
Burden percentile minus active-trial percentile within the same scope. Positive values flag cancers with high mortality burden but comparatively few active trials. A quantitative signal, not an accusation (CLAUDE.md §324). Caveat (Phase 1): trial counts aggregate a cancer and its NCIt descendants only; registrations phrased at a broader level (e.g. "colorectal cancer" for colon and rectal cancer) are attributed to the broader entity, which can overstate the gap of narrower top-level sites.
Computedci-trial-gap-v1unit: percentile pointshigher = worseAll metrics
| Rank | Δ | Cancer | Trial Gap Index (percentile points) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Colon Neoplasm | +50 | 100 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602129 |
| 2 | = | Malignant Bladder Neoplasm | +23.3 | 96.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602130 |
| 3 | = | Cutaneous Melanoma | +20 | 93.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602131 |
| 4 | = | Malignant Laryngeal Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602133 |
| 4 | = | Malignant Pancreatic Neoplasm | +16.7 | 90 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602132 |
| 6 | = | Malignant Vulvar Neoplasm | +13.4 | 83.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602134 |
| 7 | = | Malignant Vaginal Neoplasm | +6.7 | 80 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602135 |
| 8 | = | Malignant Esophageal Neoplasm | +3.4 | 76.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602136 |
| 9 | = | Malignant Testicular Neoplasm | +3.3 | 73.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602137 |
| 10 | = | Malignant Kidney Neoplasm | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602139 |
| 10 | = | Malignant Mesothelioma | +3.3 | 70 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602138 |
| 12 | = | Malignant Anal Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602144 |
| 12 | = | Malignant Liver Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602142 |
| 12 | = | Malignant Lung Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602140 |
| 12 | = | Malignant Prostate Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602143 |
| 12 | = | Malignant Rectal Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602145 |
| 12 | = | Malignant Salivary Gland Neoplasm | 0 | 63.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602141 |
| 18 | = | Malignant Thyroid Gland Neoplasm | -3.3 | 43.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602146 |
| 19 | = | Malignant Breast Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602147 |
| 19 | = | Malignant Central Nervous System Neoplasm | -3.4 | 40 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602148 |
| 21 | = | Malignant Hypopharyngeal Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602149 |
| 21 | = | Malignant Penile Neoplasm | -6.7 | 33.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602150 |
| 23 | = | Malignant Ovarian Neoplasm | -6.7 | 26.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602151 |
| 24 | = | Leukemia | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602152 |
| 24 | = | Malignant Uterine Corpus Neoplasm | -10 | 23.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602153 |
| 26 | = | Malignant Gastric Neoplasm | -13.4 | 16.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602154 |
| 27 | = | Multiple Myeloma | -16.6 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602155 |
| 27 | = | Non-Hodgkin Lymphoma | -16.6 | 13.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602156 |
| 29 | = | Hodgkin Lymphoma | -16.7 | 6.7 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602157 |
| 30 | = | Malignant Cervical Neoplasm | -20 | 3.3 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602158 |
| 31 | = | Malignant Nasopharyngeal Neoplasm | -30 | 0 | Medium confidence | cdc-uscsclinicaltrialscdc-wonderseeriarc-globocan | inputs
ranking row 2602159 |
Data updated 16 hours agoSource updated unknown31 eligible entities · inputs hash 5d76a051c6c973e09a0d5182